Research programme: anticancer therapeutics - Genentech/Xenetic Biosciences

Drug Profile

Research programme: anticancer therapeutics - Genentech/Xenetic Biosciences

Alternative Names: Cancer compound - Genentech/Lipoxen

Latest Information Update: 11 Apr 2017

Price : $50

At a glance

  • Originator Genentech; Lipoxen Technologies
  • Developer Genentech; Xenetic Biosciences
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 27 Mar 2017 Xenetic Biosciences has patent protection for PolyXen™ platform technology in Europe, Asia and North America, including USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top